Selecting the best treatment for an individual patient

Recent Results in Cancer Research

Volumn 196, Issue , 2012, Pages 307-318

  Bittoni, Alessandro ^a   Faloppi, Luca ^a   Giampieri, Riccardo ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; OROTATE PHOSPHORIBOSYLTRANSFERASE; PLACEBO; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRASTUZUMAB;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; DIGESTIVE SYSTEM CANCER; GASTRECTOMY; HUMAN; LYMPH NODE DISSECTION; METASTASIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RISK REDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER;

EID: 84870019676     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-31629-6_20     Document Type: Review

References (30)

1. Bajetta E, Buzzoni R, Mariani L et al (2002) Adjuvant chemotherapy in gastric cancer: 5-year results of a randomized study by the Italian trials in medical oncology (ITMO) group. Ann Oncol 13: 299-307
2. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697
3. Boige V, Pignon J, Saint-Aubert B et al (2007) Final results of randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of the stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 25 (18S):4510
4. Bouche' O, Ychou M, Burtin P et al (2005) Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 16: 1488-1497
5. Buyse ME, Pignon J (2009) Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer. J Clin Oncol 27:15s (suppl; abstr 4539)
6. Cascinu S, La bianca R, Barone C et al (2007) Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 99: 601-607
7. Cunningham D, Allum W, Stenning S et al (2006a) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20
8. Cunningham D, Allum WH, Stenning SP et al (2006b) MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20
9. Di Costanzo F, Gasperoni S, Manzione L et al (2008) Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 100: 388-398
10. Earle CC, Maroun JA (1999) Adjuvant chemotherapy after resection for gastric cancer in non- Asian patients. Revisiting a meta-analysis of randomized trials. Eur J Cancer 35: 1059-1064
11. Fernandez-Contreras ME, Sanchez-Prudencio S et al (2006) Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Int J Oncol 28 (5): 1303-1310
12. Gosens MJ, Moerland E et al (2008) Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int J Cancer 123: 1941-1949
13. Gusella M, Frigo AC, Bolzonella C et al (2009) Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer 100 (10): 1549-1557. Epub 2009 Apr 21
14. Hermans J, Bonekamp JJ, Bon MC et al (1993) Adjuvant therapy after resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11: 1441-1447
15. Ilson D, Bains M, Rizk N et al (2009) Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: preliminary safety analysis. J Clin Oncol 27 (15 Suppl):4573
16. Kang Y, Ohtsu A, Van Cutsem E et al (2010) AVAGAST: a randomized, double- blind, placebocontrolled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC) [abstractLBA4007]. JClinOncol 28 (18 Suppl):950S
17. Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730
18. Macdonald JS, Benedetti J, Smalley S et al (2009) Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 27:15s (suppl; abstr 4515)
19. Mari M, Floriani I, Tinazzi A et al (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis for published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 11: 837-843
20. Okines AF, Langley R, Cafferty FH et al (2010) Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma. J Clin Oncol 28 (15 Suppl):4019
21. Okines AF, Reynolds AR, Cunningham D (2011) Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist 16 (6): 844-858. Epub 2011 May 31. Review
22. Paez D, Pare L, et al (2010) Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. J Cancer Sci 101 (9): 2048-2053. doi: 10.1111/j.1349-7006.2010. 01621.x
23. Panzini I, Gianni L, Fattori PP et al (2002) Adjuvant chemotherapy in gastric cancer: a metaanalysis of randomized trials and a comparison with previous metaanalyses. Tumori 88: 21-27
24. Roth et al (2007) Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized trial of the Swiss group for clinical cancer research (SAKK) and the European institute of oncology (EIO). World Congress on Gastrointestinal Cancer
25. Scartozzi M, Galizia E, Graziano F et al (2005) Over-D1 dissection may question the value of radiotherapy as a part o fan adjuvant programme in high-risk radically resecate gastric cancer patients. Br J Cancer 92: 1051-1054
26. Scartozzi M, Galizia E, Chiorrini S et al (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20: 227-230
27. Schuhmacher C, Schlag P, Lordick F et al (2009) Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. J Clin Oncol 27:15s (suppl; abstr 4510)
28. Stahl M, Walz KM, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27: 851-856
29. Suh KW, Kim JH et al (2005) Thymidylate Synthase Gene Polymorphism as a Prognostic Factor for Colon Cancer. J Gastrointest Surg 9: 336-342
30. Villafranca E, Okruzhnov Y et al (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19: 1779-1786